PRIMA-1

Overview

PRIMA-1 (NSC-281668) is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-19980A
• CAS No.: 5608-24-2
• Molecular Formula: C9H15NO3
• Molecular Weight: 185.22
• Purity: 98.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (13.50 mM); Clear solution
• Availability: In-stock

Source

Original product source